The US government has suspended the distribution of monoclonal antibodies against the coronavirus by the drug companies Regeneron and Eli Lilly, saying that they are probably ineffective in treating the Omicron mutation.
The new strain has taken hold in the United States as it spreads rapidly, forcing the government to reinstate restrictive measures to stem the tide of new pandemics.
Discontinuation of these treatments will take effect until new data on their effectiveness emerge, the Food and Drug Administration said.
German researchers have found in laboratory tests that Eli Lilly and Regeneron treatments lose most of their effectiveness when exposed to Omicron.
U.S. officials, however, said that GlaxoSmithKline’s competing drug sotrovimab and Vir Biotechnology appeared to be working against the new mutation.
Shipments of Sotrovimab, which were discontinued last month pending efficacy data against the mutation, have resumed and delivery of 55,000 doses of the drug has begun, authorities said.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
